NCT04432857 - AN0025 and Pembrolizumab Combination in Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 20, 2020

Primary Completion Date

May 31, 2024

Study Completion Date

January 30, 2025

Conditions

Triple-negative Breast CancerNSCLC, Squamous or Non-SquamousUrothelial Carcinoma of the BladderMicrosatellite Stable (MSS) Colorectal Cancer (CRC)Cervical Cancer

Interventions

DRUG

AN0025

oral administration

DRUG

Pembrolizumab

Infusion

Trial Locations (6)

22908

University of Virginia, Richmond

63110

Washington University School of Medicine - Siteman Cancer Center, St Louis

77030

MD Anderson Cancer Center, Houston

84112

University of Utah School of Medicine Huntsman Cancer Institute, Salt Lake City

94805

Gustave Roussy, Paris

Unknown

Centre Léon Bérard, Lyon

All Listed Sponsors

collaborator

Merck Sharp & Dohme LLC

INDUSTRY

lead

Adlai Nortye Biopharma Co., Ltd.

INDUSTRY